An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors.

Trial Profile

An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2017

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Advanced breast cancer; Brain metastases; Endometrial cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Solid tumours; Testicular cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov
    • 26 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top